RNAConnect

Executive Summary

RNAConnect is a San Diego-based biotechnology company founded in 2020 that develops and commercializes ultra-performance enzymatic tools for RNA analysis and manipulation. Its proprietary reverse transcriptase platform enables more accurate and comprehensive RNA sequencing, particularly for long, structured, or low-abundance RNAs, addressing key limitations in current RNA research. The company's products are designed to accelerate research and development across basic discovery, diagnostics, and next-generation cell, gene, and RNA therapies. By providing superior enzymes for RNA manipulation, RNAConnect positions itself as a critical enabler in the rapidly growing RNA therapeutics field, which is witnessing increased investment and clinical progress. The company is privately held and has not disclosed funding or valuation, but its technology platform has the potential to become the standard for RNA sequencing, driving adoption among academic and pharmaceutical customers.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation reverse transcriptase for long-read RNA sequencing80% success
• Q4 2026Strategic partnership with a top-10 RNA therapeutics company for discovery services60% success
• Q2 2026Series A funding round to scale commercial operations and expand product portfolio70% success